Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16447915 | 0.99 | BRD4 (0.37) | BRD4NR4A2GAAKDM4EPOLB | |
| SCHEMBL18567026 | 0.93 | HTT (0.35) | BRD4NR4A2GAAKDM4EPOLB | |
| SCHEMBL15084354 | 0.92 | BRD4 (0.36) | BRD4NR4A2GAAKDM4EPOLB | |
| SCHEMBL2415069 | 0.92 | KDM4E (0.38) | BRD4NR4A2GAAKDM4EPOLB | |
| SCHEMBL17967309 | 0.91 | PDE3B (0.33) | BRD4NR4A2GAAKDM4EPOLB | |
| SCHEMBL19755582 | 0.88 | BRD4 (0.37) | BRD4NR4A2GAAKDM4EPOLB | |
| SCHEMBL19245942 | 0.87 | BRD4 (0.39) | BRD4NR4A2GAAKDM4EPOLB | |
| SCHEMBL15015205 | 0.85 | BRD4 (0.36) | BRD4NR4A2GAAKDM4EALDH1A1 | |
| SCHEMBL21284549 | 0.83 | ALDH1A1 (0.31) | POLBALDH1A1LMNAL3MBTL1KMT2A | |
| SCHEMBL18473879 | 0.82 | HPGD (0.45) | BRD4NR4A2GAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116003435-A | Efficient green preparation method of dolutegravir | 河南师范大学 | 2023-04-25 | — | — | CN | claimed |
| CN-115746022-A | Preparation method and application of caspovir derivative | 河南科技大学 | 2023-03-07 | — | — | CN | claimed |
| US-20190106435-A1 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES | VIIV HEALTHCARE COMPANY | 2019-04-11 | — | — | US | claimed |
| EP-3260457-A1 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES | VIIV Healthcare Company (US) | 2017-12-27 | — | — | EP | claimed |
| EP-2549870-B1 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES | VIIV HEALTHCARE CO (US) | 2017-04-19 | — | — | EP | claimed |
| US-20130172551-A1 | Process for Preparing Carbamolypyridone Derivatives and Intermediates | VIIV HEALTHCARE COMPANY | 2013-07-04 | — | — | US | claimed |
| CN-116496296-A | Dolutegravir derivative with anti-tumor function and preparation method thereof | 河南师范大学 | 2023-07-28 | — | — | CN | disclosed |
| US-10730888-B2 | Process for the preparation of dolutegravir | MYLAN LABORATORIES LIMITED (IN) | 2020-08-04 | — | — | US | disclosed |
| US-10730888-B2 | Process for the preparation of dolutegravir | MYLAN LABORATORIES LIMITED (IN) | 2020-08-04 | — | — | US | disclosed |
| US-10696636-B2 | Process for the preparation of HIV integrase inhibitors | LUPIN LIMITED (IN) | 2020-06-30 | — | — | US | disclosed |
| US-20200172487-A1 | PROCESS FOR THE PREPARATION OF HIV INTEGRASE INHIBITORS | LUPIN MANUFACTURING SOLUTIONS LIMITED (IN) | 2020-06-04 | — | — | US | disclosed |
| US-10654871-B2 | Process for preparing (3S,11aR)-N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide | VIIV HEALTHCARE COMPANY (US) | 2020-05-19 | — | — | US | disclosed |
| CN-107531614-B | Preparation method of delogevir | 迈兰实验室有限公司 | 2020-04-10 | — | — | CN | disclosed |
| US-9573965-B2 | Process for the preparation of Dolutegravir | AUROBINDO PHARMA LTD (IN) | 2017-02-21 | — | — | US | disclosed |
| WO-2016125192-A2 | PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR | MYLAN LABORATORIES LIMITED (IN) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016125192-A2 | PROCESS FOR THE PREPARATION OF DOLUTEGRAVIR | MYLAN LABORATORIES LIMITED (IN) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016113372-A1 | PROCESSES FOR PREPARING DOLUTEGRAVIR AND CABOTEGRAVIR AND ANALOGUES THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2016-07-21 | — | — | WO | disclosed |
| EP-3045461-A1 | Processes for preparing dolutegravir and analogues thereof | LEK Pharmaceuticals d.d. (SI) | 2016-07-20 | — | — | EP | disclosed |
| WO-2015019310-A1 | PROCESS FOR THE PREPARATION OF DOLUTE-GRAVIR AND INTERMEDIATES THEREOF | MYLAN LABORATORIES LTD (IN) | 2015-02-12 | — | — | WO | disclosed |
| WO-2015019310-A1 | PROCESS FOR THE PREPARATION OF DOLUTE-GRAVIR AND INTERMEDIATES THEREOF | MYLAN LABORATORIES LTD (IN) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696636-B2 | Process for the preparation of HIV integrase inhibitors | XDH, APOBEC3C, APOBEC3G | BRD4 2354/4885NR4A2 2246/4885GAA 1712/4885 |
| US-10730888-B2 | Process for the preparation of dolutegravir | SAMHD1, TYMP, DUT | BRD4 3777/4885NR4A2 4458/4885GAA 667/4885 |
| US-20190106435-A1 | PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES | CPS1, CYP3A4, SDHA | BRD4 620/4885NR4A2 2883/4885GAA 1770/4885 |
| US-20200172487-A1 | PROCESS FOR THE PREPARATION OF HIV INTEGRASE INHIBITORS | XDH, APOBEC3C, APOBEC3G | BRD4 2354/4885NR4A2 2246/4885GAA 1712/4885 |
| US-20130172551-A1 | Process for Preparing Carbamolypyridone Derivatives and Intermediates | CPS1, CYP3A4, DHPS | BRD4 341/4885NR4A2 2590/4885GAA 3024/4885 |
| US-10654871-B2 | Process for preparing (3S,11aR)-N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide | CYP4B1, CYP2F1, CYP4F11 | BRD4 1652/4885NR4A2 1684/4885GAA 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.